Publications by authors named "Garett Michael"
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
J Clin Oncol
November 2022
Purpose: To examine COVID-19 mRNA vaccine-induced binding and neutralizing antibody responses in patients with non-small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (wild type [WT]) strain and variants of concern after the primary 2-dose and booster vaccination.
Methods: Eighty-two patients with NSCLC and 53 healthy volunteers who received SARS-CoV-2 mRNA vaccines were included in the study. Blood was collected longitudinally, and SARS-CoV-2-specific binding and neutralizing antibody responses were evaluated by Meso Scale Discovery assay and live virus Focus Reduction Neutralization Assay, respectively.
Article Synopsis
- The study focused on the antibody response to SARS-CoV-2 mRNA vaccines in non-small cell lung cancer (NSCLC) patients compared to healthy adults, examining their reactions to various virus strains, including Delta and Omicron.
- Results indicated NSCLC patients had significantly lower binding and neutralizing antibodies, particularly against the Delta (6-fold reduction) and Omicron (79-fold reduction) variants, compared to healthy individuals.
- The analysis also revealed that older patients (over 70) had lower antibody levels, while other factors like cancer treatments had no significant impact on the overall antibody response.
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how effective antibodies from people who had COVID-19 or were vaccinated respond to new SARS-CoV-2 variants, specifically B.1 and B.1.351.
- Researchers found that both groups showed a notable decrease in antibody levels when confronting the B.1.351 variant compared to the original B.1 variant.
- Despite these reductions, many antibodies still effectively neutralized the B.1.351 variant, indicating that immunity against COVID-19 is still largely maintained.